Business
Avicanna Reports Q1 2025 Results and First Profitable Quarter
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q1 2025 and the of the Company’s milestone of achieving its first profitable quarter. Management Commentary: "Starting 2025 with positive momentum, we are proud to report our first profitable
About this update from Avicanna Inc
[{"type":"image","alt":"Avicanna Inc.","displaySize":"","headline":null,"caption":"Avicanna Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/1c68da9c20a644cdc756241b8ad53506"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vToBXKkzxq5ehGv_5f_3zA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1c68da9c20a644cdc756241b8ad53506","width":300,"height":300}},"lazy":false},{"type":"text","content":"TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q1 2025 and the of the Company’s milestone of achieving its first profitable quarter.","length":394,"tagName":"p"},{"type":"text","content":"Management Commentary: "Starting 2025 with positive momentum, we are proud to report our first profitable quarter—a milestone that reflects our strategic focus and operational discipline. With this solid foundation, we are now positioned to focus on scaling our Canadian operations, international expansion, and advancing of our R&D pipeline and intellectual property" stated Aras Azadian, CEO of Avicanna.","length":421,"tagName":"p"},{"type":"text","content":"Q1 2025 Financial Highlights:","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First Profitable Quarter: Net income of $74,154 and comprehensive income of $876,092, driven by cost efficiencies and margin improvements.","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted Positive EBITDA: Adjusted positive EBITDA of approximately $431,000, reflecting a significant year-over-year improvement from approximately $18,000 in Q1 2024.","length":168,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross Profit and Gross Margins: Gross profit of $3.54 million in Q1 2025, a 7% increase year-over-year. Consolidated gross margins improved to 56% in Q1 2025, up from 51% in Q1 2024, driven by portfolio optimization and a substantial increase in licensing and service revenue.","length":276,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenue Performance: Revenue o...